TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-and Long-term Effects of a Home-based Rehabilitation Program on Functional Capacity, Peripheral Muscle Strength and Quality of Life in Patients With Bronchiectasis: Randomized Controlled Trial
Brief Summary: This study will investigate the short-and long-term effects of the home-based pulmonary rehabilitation on peripheral muscle strength, functional capacity and quality of life in patients with bronchiectasis. The participants will be randomized into two groups: control group (usual care and recommendations for practice exercise) and training group, that will perform aerobic (stepping training) and resistance training (lower and upper limbs) for eight weeks, three times a week. At baseline, immediately after finishing and after six months the patients will undergo assessments.


Options:
A: Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Training Group | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: Training Group; Assigned to Arm(s): Training Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
B: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation
C: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
D: Arm Label: Airway clearance, bronchiectasis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Low Expiration Open glottis inferolateral (ELTGOL) | Arm Label: bronchiectasis, stretching; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Stretching | Intervention Type: PROCEDURE; Name: Low Expiration Open glottis inferolateral (ELTGOL); Assigned to Arm(s): Airway clearance, bronchiectasis | Intervention Type: PROCEDURE; Name: Stretching; Assigned to Arm(s): bronchiectasis, stretching

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation Research for Vulnerable Women in South Africa
Brief Summary: This study sought to implement the Women's Health CoOp (Cooperative) (WHC) intervention into healthcare, antenatal, and substance treatment clinics in South Africa and translated this evidence-based intervention into real-world settings. Implementation, service, and patient outcomes will be evaluated through an iterative stepped wedge design.


Options:
A: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
B: Arm Label: Women's Health CoOp (WHC); Type: EXPERIMENTAL; Interventions: Behavioral: Women's Health CoOp (WHC) | Intervention Type: BEHAVIORAL; Name: Women's Health CoOp (WHC); Assigned to Arm(s): Women's Health CoOp (WHC)
C: Arm Label: advocacy intervention; Type: EXPERIMENTAL; Interventions: Behavioral: advocacy intervention | Arm Label: Usual community services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual community services | Intervention Type: BEHAVIORAL; Name: advocacy intervention; Assigned to Arm(s): advocacy intervention | Intervention Type: BEHAVIORAL; Name: usual community services; Assigned to Arm(s): Usual community services
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: The SHARE Project | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The SHARE Project; Assigned to Arm(s): Intervention arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2
Brief Summary: This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: pembrolizumab | Intervention Type: DRUG; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab
C: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
D: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Medication Review on Hospital Readmission: Study Protocol of a Randomized Controlled Trial
Brief Summary: The study is a randomized controlled clinical trial. A total 1400 hospitalized patients will be randomized in two groups:

1. group receiving a pharmacist-led standardized medication review (experimental group); and
2. group not receiving the medication review (control group).

The patients will be followed up at 30 days after initial hospitalization. Outcome measures include the number of readmissions; patient satisfaction, quality of medical admission prescription and number of consultation after initial hospitalization.

Discussion: A randomized controlled trial will provide the highest level of evidence on the impact of pharmacist-led standardized medication review on early hospital readmission for extreme age population.


Options:
A: Arm Label: standard course; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Arm Label: pharmacist-led standardized medication review; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Intervention Type: OTHER; Name: pharmacist-led standardized medication review; Assigned to Arm(s): pharmacist-led standardized medication review, standard course
B: Arm Label: Pharmacist Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist-led Hospital Discharge Care Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacist-led Hospital Discharge Care Intervention; Assigned to Arm(s): Pharmacist Arm
C: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A
D: Arm Label: Application of STOPP/START criteria; Type: ACTIVE_COMPARATOR; Interventions: Other: Application of STOPP/START criteria | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Normal pharmaceutical care | Intervention Type: OTHER; Name: Application of STOPP/START criteria; Assigned to Arm(s): Application of STOPP/START criteria | Intervention Type: OTHER; Name: Normal pharmaceutical care; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery: a Randomized, Placebo Controlled Trial
Brief Summary: The objective of this study is to determine whether maintaining a eugonadal state, during severe, sustained energy deficit, attenuates physiological decrements, particularly the loss of lean body mass.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reandron 1000 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Reandron 1000; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
C: Arm Label: Energy Deficit; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sesame Oil | Arm Label: Energy Deficit + Testosterone; Type: EXPERIMENTAL; Interventions: Drug: testosterone enanthate | Intervention Type: DRUG; Name: Sesame Oil; Assigned to Arm(s): Energy Deficit | Intervention Type: DRUG; Name: testosterone enanthate; Assigned to Arm(s): Energy Deficit + Testosterone
D: Arm Label: Testim; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): Testim | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Clinical Trial to Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children
Brief Summary: The purpose of this project is to evaluate in a randomized clinical trial, double-blind, controlled, the effects of a dietary supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 in reducing bronchial inflammation and improve asthma control in patients in children with mild / moderate persistent asthma .


Options:
A: Arm Label: Reuterin D3 drops; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reuterin D3 drops | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Reuterin D3 drops; Assigned to Arm(s): Reuterin D3 drops | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo
C: Arm Label: vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: vitamin D3 4000 IU | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: vitamin D3 4000 IU; Assigned to Arm(s): vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: daily vitamin D supplement, Other: Placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: daily vitamin D supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: daily vitamin D supplement; Assigned to Arm(s): Placebo, Vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects
Brief Summary: This was a multi-centre, randomized, investigator blinded, vehicle controlled trial using intra-individual comparison (right half-face versus left half-face).

Participants with each half-face randomized to one of the two following treatments:

* Adapalene 0.3 percent (%) - benzoyl peroxide (BPO) 2.5% gel (TactuPump® Forte).
* Vehicle gel

The main objective of this trial was to evaluate the effect of Adapalene 0.3% - BPO 2.5% (ABPO Forte) gel versus vehicle gel on the risk of formation of atrophic acne scars in moderate to severe acne participants.


Options:
A: Arm Label: Duac & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | Arm Label: Acanya & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene | Intervention Type: DRUG; Name: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene; Assigned to Arm(s): Duac & taz | Intervention Type: DRUG; Name: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene; Assigned to Arm(s): Acanya & taz
B: Arm Label: Duac™Once Daily Gel; Type: EXPERIMENTAL; Interventions: Drug: 1% clindamycin phosphate gel | Arm Label: 1% clindamycin phosphate gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duac™Once Daily Gel | Intervention Type: DRUG; Name: Duac™Once Daily Gel; Assigned to Arm(s): 1% clindamycin phosphate gel | Intervention Type: DRUG; Name: 1% clindamycin phosphate gel; Assigned to Arm(s): Duac™Once Daily Gel
C: Arm Label: CD0271 0.3% /CD1579 2.5% Gel; Type: EXPERIMENTAL; Interventions: Drug: CD0271 0.3% / CD1579 2.5% | Arm Label: CD0271 0.1% / CD1579 2.5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD0271 0.1% / CD1579 2.5% | Arm Label: Topical Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical Gel Vehicle | Intervention Type: DRUG; Name: CD0271 0.3% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.3% /CD1579 2.5% Gel | Intervention Type: DRUG; Name: CD0271 0.1% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.1% / CD1579 2.5% | Intervention Type: DRUG; Name: Topical Gel Vehicle; Assigned to Arm(s): Topical Gel Vehicle
D: Arm Label: Part 1: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 1: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Arm Label: Part 2: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 2: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: ABPO Forte Gel; Assigned to Arm(s): Part 1: ABPO Forte Gel, Part 2: ABPO Forte Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Part 1: ABPO Forte Vehicle Gel, Part 2: ABPO Forte Vehicle Gel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Cold Saline Used to Inflate a Balloon Tamponade Catheter More Significantly Reduce Blood Loss From Postpartum Hemorrhage Than Room Temperature Saline?
Brief Summary: To determine if a balloon tamponade catheter filled with cold saline is more effective than a catheter filled with room temperature saline in controlling post partum hemorrhage.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Device: non-pneumatic anti-shock garment | Intervention Type: DEVICE; Name: non-pneumatic anti-shock garment; Assigned to Arm(s): Intervention
B: Arm Label: Room temperature arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Cold Bakri Balloon | Arm Label: Cold arm; Type: EXPERIMENTAL; Interventions: Device: Cold Bakri Balloon | Intervention Type: DEVICE; Name: Cold Bakri Balloon; Assigned to Arm(s): Cold arm, Room temperature arm
C: Arm Label: Tampostat; Type: EXPERIMENTAL; Interventions: Device: Tampostat | Arm Label: Condom catheter tamponade; Type: ACTIVE_COMPARATOR; Interventions: Device: Condom catheter tamponade | Intervention Type: DEVICE; Name: Tampostat; Assigned to Arm(s): Tampostat | Intervention Type: DEVICE; Name: Condom catheter tamponade; Assigned to Arm(s): Condom catheter tamponade
D: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Brief Summary: This study plans to test the pathologic complete response (pCR) rate of the combination biotherapy regimen consisting of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced but operable melanoma. Evaluation of the presence of tumor-infiltrating CD8+ T cells as well as that of PDL1 expression and IDO expression will be associated with clinical response (pathologic and/or radiologic). The study will test the radiologic/clinical preoperative response rate, recurrence free survival (RFS) and overall survival (OS). It will evaluate the safety of neoadjuvant nivolumab and neoadjuvant nivolumab-ipilimumab. Up to 66 patients will be randomized in 1:1 ratio.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Intervention Type: PROCEDURE; Name: Surgery of the tumor; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with ipilimumab 3 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with nivolumab 1 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B
B: Arm Label: vemurafenib + cobimetinib + atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib, Drug: Atezolizumab | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab
C: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: hu14.18-IL2 | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): A | Intervention Type: DRUG; Name: hu14.18-IL2; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Brief Summary: This study plans to test the pathologic complete response (pCR) rate of the combination biotherapy regimen consisting of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced but operable melanoma. Evaluation of the presence of tumor-infiltrating CD8+ T cells as well as that of PDL1 expression and IDO expression will be associated with clinical response (pathologic and/or radiologic). The study will test the radiologic/clinical preoperative response rate, recurrence free survival (RFS) and overall survival (OS). It will evaluate the safety of neoadjuvant nivolumab and neoadjuvant nivolumab-ipilimumab. Up to 66 patients will be randomized in 1:1 ratio.


Options:
A: Arm Label: Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Arm Label: Pembrolizumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab Q3W; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab Q2W, Pembrolizumab Q3W | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab
B: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
C: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Drug: vemurafenib | Intervention Type: DRUG; Name: vemurafenib; Assigned to Arm(s): Single arm
D: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab

Answer: B